Neoadjuvant Chemoradiotherapy of Rectal Carcinoma with Bevacizumab
Authors:
P. Šlampa
Authors‘ workplace:
Klinika radiační onkologie, LF MU a Masarykův onkologický ústav, Brno
Published in:
Klin Onkol 2011; 24(5): 338-342
Category:
Reviews
Overview
Concomitant chemoradiotherapy and radical surgery are standard methods of treatment in patients with locally advanced rectal carcinoma. Neoadjuvant chemoradiotherapy with 5-fluorouracil or capecitabine is considered to be an optimal treatment approach. Clinical studies attempt to facilitate treatment response to neoadjuvant chemoradiotherapy by adding targeted biological therapy. Anti-angiogenic effect of bevacizumab may potentiate radiosenzitivity. We present an overview of standard methods of treatment of rectal carcinoma and a summary of published results of neoadjuvant chemoradiotherapy with bevacizumab in the treatment of rectal carcinoma. At present, this combination is not considered to be a standard procedure of neoadjuvant treatment in the Czech Republic. However, based on the results of forthcoming clinical studies, wider use of this concomitant chemobioradiotherapy in clinical practice can be expected, especially in the treatment of locally advanced stages of rectal carcinoma.
Key words:
rectal carcinoma – neoadjuvant chemoradiotherapy – biological therapy – bevacizumab
The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
Submitted:
17. 4. 2011
Accepted:
25. 5. 2011
Sources
1. Šlampa P. Konkomitantní radiochemoterapie solidních nádorů. Brno: KAP 2000: 5–16.
2. Šlampa P, Soumarová R, Kocáková I et al. Konkomitantní chemoradioterapie solidních nádorů. Praha: Galén 2005: 17–52.
3. Svoboda T. Antiangiogenní léky v klinické praxi. Klin Farmakol Farm 2010; 24(3): 127–134.
4. Šlampa P et al. Radiační onkologie v praxi. 2. aktual. vyd. Brno: MOÚ 2007: 47–52.
5. Doleželová H, Ondrová B, Hynková L. Moderní radioterapie v léčbě kolorektálního karcinomu. In: Vyzula R, Žaloudík J et al (eds). Rakovina tlustého střeva a konečníku: vybrané kapitoly. Praha: Maxdorf 2007: 205–217.
6. Šlampa P, Petera J et al. Radiační onkologie. Praha: Galén-Karolinum 2007: 153–162.
7. Šlampa P, Lovas P. Úloha kombinované radiochemoterapie u lokálně pokročilých nádorů rekta. Acta Chemo-therapeutica 2009; 18(2): 27–29.
8. Cervantes A, Rosselló S, Rodríguez-Braun E et al. Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. Ann Oncol 2008; 19 (Suppl 7): vii266–vii272.
9. Glimelius B, Påhlman L, Cervantes A. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v82–v86.
10. Valentini V, Aristei C, Glimelius B et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 2009; 92(2): 148–163.
11. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008; 26(2): 303–312.
12. Swellengrebel HA, Marijnen CA, Verwaal VJ et al. Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. Br J Surg 2011; 98(3): 418–426.
13. Kocáková I, Kocák I, Svoboda M et al. Bevacizumab v kombinaci s kapecitabinem a irinotekanem (Xeliri) v léčbě metastatického kolorektálního karcinomu. Klin Onkol 2009; 22(2): 73–76.
14. Kocáková I. Bevacizumab v 1. a dalších linií léčby nemocných s kolorektálním karcinomem. Farmakoterapie 2009; 5: 74–80.
15. Czito BG, Willett CG. Rationale, Design, and Results of Clinical Trials Combining Radiotherapy With Antiangiogenic Therapy in Rectal Cancer. MedScape 2007. Available from: www.medscape.org/viewarticle/563025_3.
16. Crane CH, Eng C, Feig BW et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal carcinoma. Int J Radiat Oncol Biol Phys 2010; 76(3): 824–830.
17. Krishnan S, Janjan NA, Skibber JM et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66(3): 762–771.
18. Saif M, Hashmi S, Zelterman D et al. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis 2008; 32(2): 139–145.
19. Gérard JP, Azria D, Gourgou-Bourgade S et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28(10): 1638–1644.
20. Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer – is the water getting muddy? Acta Oncol 2010; 49(3): 278–286.
21. Velenik V, Ocvirk J, Oblak I. Neoadjuvant cetuximab, capecitabine, and radiotherapy in locally advanced resectable rectal cancer: results of a phase II trial. J Clin Oncol 2009; 27 (Suppl-ASCO): Abstract e15029.
22. Willet CG, Duda DG, di Tomaso E et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27(18): 3020–3026.
23. Koukourakis MI, Giatromanolaki A, Tsoutsou P et al. Bevacizumab, capecitabin, amifostine, and prepoperative hypofractionated accelerated radiotherapy (HypoARC) for rectal cancer: a phase II study. Int J Radiat Oncol Biol Phys 2011; 80(2): 492–498.
24. Velenik V, Ocvirk J, Omejc M et al. Neoadjuvant bevacizumab, capecitabine, and radiotherapy in locally advanced rectal cancer: Interim results of a phase II CRAB trial. J Clin Oncol 2010; 28 (Suppl 15): Abstract e14006.
25. Villacampa MM, Santos C, García M et al. Phase II study of preoperative bevacizumab, capecitabine, and radiotherapy for resectable locally advanced rectal cancer. J Clin Oncol 2011; 29 (Suppl 4): Abstract 516.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2011 Issue 5
Most read in this issue
- Partial Regression of CNS Lesions of Erdheim-Chester Disease after Treatment with 2-chlorodeoxadenosine and Their Full Remission Following Treatment with Lenalidomide
- Neuroendoscopic Biopsy of a Brain Tumor
- Secondary Angiosarcomas after Conservation Treatment for Breast Cancers
- Hsp90 – a Target for Anticancer Therapy